Rediff.com  » News » Covaxin gets nod for phase 2, 3 clinical trials on 2-18 year-olds

Covaxin gets nod for phase 2, 3 clinical trials on 2-18 year-olds

By Payal Banerjee
May 12, 2021 12:01 IST
Get Rediff News in your Inbox:

Bharat Biotech's COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said.

IMAGE: Kindly note that this image has been posted for representational purposes only.

The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.

The Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organization on Tuesday deliberated upon Hyderabad-based Bharat Biotech's application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.

 

"After detailed deliberation, the committee recommended for conduct of proposed phase II/III clinical trial of whole virion inactivated coronavirus vaccine in the 2 to 18 years age group subject to the condition that the firm should submit the interim safety data of phase II clinical trial along with DSMB recommendations to the CDSCO before proceeding to phase III part of the study," a source said.

Earlier the proposal was deliberated in the SEC meeting dated February 24 and the firm was asked to submit a revised clinical trial protocol.

Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, is being used in adults in India's ongoing COVID-19 vaccination drive.

Get Rediff News in your Inbox:
Payal Banerjee
Source: PTI© Copyright 2021 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.
SHARE THIS STORY 
The War Against Coronavirus

The War Against Coronavirus